We develop cancer treatment with no or low side effects
Hamlet Pharma provides new therapeutic solutions for targeting and killing tumor cells with greater precision.
Latest news
Hamlet Pharma advertises in major health supplement published in one of the world’s leading international newspapers, The Guardian
An advertorial by Hamlet Pharma was published in The Guardian on December 6th. Entitled “Successful new drug candidate for patients with bladder cancer – from…
Read More
Executive Summary
Hamlet Pharma provides new therapeutic solutions for targeting and killing tumor cells with greater precision.
- The parent compound HAMLET shows broad anti-tumor effects in animal models and clinical trials
- The 2nd generation, synthetic drug candidate Alpha1H kills a variety of cancer cells.
- Therapeutic efficacy of Alpha1H has been demonstrated in controlled clinical trials.
- Recent successful outcomes include
-
- a placebo-controlled study of bladder cancer, showing therapeutic efficacy without detectable toxicity
(Link: Nature Communications ) - A dose escalation study, showed increased efficacy with higher doses of Alpha1H.
- a placebo-controlled study of bladder cancer, showing therapeutic efficacy without detectable toxicity
- Hamlet Pharma’s IP includes about 50 patents and patent applications, world-wide.
- Hamlet Pharma’s drug development pipeline includes:
-
- Alpha1H for brain tumors (with international key opinion leaders).
- Bovine HAMLET, BAMLET, is under development for clinical trials in colon cancer and oral cancer.
- BAMLET is also of interest as a health food concept.
Hamlet Pharma is looking for partnering/investment to take the new drugs to the market.
Our project portfolio
Drug candidate Alpha1H
Our drug candidate Alpha1H kills tumor cells quickly and selectively. The strong effects have been validated in cell models, animal models and in treated patients, where the response can be measured already within a few hours.
Bladder cancer
Each year, around 500,000 patients worldwide are diagnosed with bladder cancer, and this number is rising. Alpha1H has been shown to kill tumor cells and significantly reducing tumor size, without harming healthy tissues, with low side effects in patients. Our clinical trials program is now moving towards Phase III.
Brain tumor
Early studies in animal models have shown that infusion of Alpha1H into the brain markedly delayed the progression of tumors. In a collaboration with Neurochase Ltd. in the UK, Alpha1H is now tested further to evaluate its potential of treating brain tumors, using proprietary method and technology of administrating drugs locally, with great precision, into the brain.
Drug Candidate BAMLET
BAMLET is a protein-complex formed by alpha lactalbumin from cow’s milk, and oleic acid. Like Alpha1H, BAMLET effectively kills cancer cells and has shown effects against growing tumor tissue. The company intends to establish production of BAMLET primarily for clinical studies for the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.
Colon cancer
Colorectal cancer is a leading cause of death world-wide and more than 180,000 cases are diagnosed annually in the US alone. Daily, long-term treatment with BAMLET in the drinking water inhibits intestinal tumor development in mice genetically susceptible to intestinal tumors. Target groups for BAMLET treatment are patients at risk of developing colon cancer and patients who already have the disease.
Oral cancer
Oral leukoplakia is a protracted process where patients first develop areas of undifferentiated cells in the oral cavity that can gradually change and become increasingly cancerous. Hamlet Pharma intends to investigate whether BAMLET can be developed into a treatment for oral leukoplakia and thereby prevent the transformation to oral squamous cell carcinoma.
Presentation and films
See all media
Our story
A research group in Lund, led by Professor Catharina Svanborg discovered in 1995 that a component of human breast milk kills tumor cells without harming mature, healthy cells.
Since the discovery, the research team has successfully worked to characterize the HAMLET structure, its mechanisms and treatment effects in animal models and in patients. HAMLET´s tumor killing abilities have since the discovery been confirmed by several international research groups working on different aspects of HAMLET.
The results have been published in prestigious journals like The New England Journal of Medicine, GUT, Nature Communication and PNAS (Proceedings of the National Academy of Science, USA).
Our science
2021
A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate
Bladder cancer therapy without toxicity—A dose-escalation study of alpha1-oleate
Our team
The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. HAMLET’s aim is to prove the efficacy of HAMLET therapy and to develop drugs that kill tumour cells with greater precision than current drugs.
Board of Directors
Catharina Svanborg
Chairman Of The Board
Ulla Trägårdh
Member of the Board
Bill Hansson
Member of the board
Helena Lomberg
Member of the Board
Executive Team
Mats Persson
Senior Advisor
Martin Erixon
CEO